CURRICULUM VITAE

David M Katz, MD


OFFICE ADDRESS:                                    Bethesda Neurology, LLC

3202 Tower Oaks Blvd, Suite 330

N Bethesda, 

301-540-2700 (office phone)

866-328-4322 (fax)


          WEBSITE:                                 BethesdaNeurology.com


SUBSPECIALTY:  Neuro-Ophthalmology                                   

SPECIALITY: Adult Neurology


EDUCATION:


UNDERGRADUATE 

Colgate University

Hamilton, NY

BA in Neuroscience      

1979-1983


MEDICAL SCHOOL   

SUNY/Buffalo School of Medicine

Buffalo, NY

1984-1988


INTERNSHIP

Millard Fillmore Hospital/SUNY Buffalo

Buffalo, NY

Internal Medicine

1988-1989


NEUROLOGY RESIDENCY 

Duke University Medical Center

Durham, NC 

Neurology Residency

1989-1992, Chief Resident: 91-92


NEURO-OPHTHALMOLOGY FELLOWSHIP 

University of Michigan Kellogg Eye Center

Ann Arbor, MI

1992-1993


BOARD CERTIFICATION: 

Diplomate, American Board of Neurology, 1994 Lifetime Certification


MEDICAL LICENSURE: 

Maryland: D0052447

DC: MD30630

Virginia: 0101232630


FACULTY APPOINTMENTS: 

Clinical Assistant Professor of Ophthalmology

Georgetown University Medical Center

Washington, DC, 2012-


Clinical Associate Professor of Ophthalmology and Neurology, and Director of Neuro-Ophthalmology Services

Howard University School of Medicine

Washington, DC, 1997-


Fellow, North American Neuro-Ophthalmology Society 2014-


HOSPITAL AFFILIATIONS:

Suburban Hospital/Johns Hopkins Medicine

Bethesda, MD, 1997-


HONORS AND AWARDS:

Steering Committee, Idiopathic Intracranial Hypertension Treatment Trial (IIHTT)

“Super Doctors”, Washington Post

“Top Neurologists”, Best Doctors

“Top Neurologists”, Consumer Checkbook

“Top Doctors”, Northern Virginia Magazine

“Neuro-Ophthalmology Medical Mystery Case” Washington Post Health Section 11/22/16

                                                                                                                                   

PROFESSIONAL SOCIETIES:

-Maryland Board of Physicians, Neurology  Consultant

-Washington Clinical Pathological Society (WCP)

-DC Area Neuro-Immunology Group (DANG)

-North American Neuro-Ophthalmology Society     (NANOS)

-Montgomery County Medical Society (MCMS)

-MedChi

-American Medical Association (AMA)


BIBLIOGRAPHY:


Yousuf, Guiseppi, Katz, et al. Emergency department presentation of retinal artery occlusion. Ophthalmol Retina 2021


Olds J, Hills W, Warner J, Falardeau J, Egan R, Cornblath W, Lee A, Frishberg B, May M, Turbin R, Katz D, Charley J, Pelak V. Posterior cortical atrophy: patient characteristics from a clinical data registry. Front in Neurol 2020,11:358-71.


Zhou Y, Walker R, Katz D, Weir R, Trouth, A. Varicella-zoster reactivation resulting in stroke and progressive outer retinal necrosis: case report and literature review. ECNeurology 2017, 6.5:238-42


Katz DM and Trobe JD. Is there treatment for nonarteritic anterior ischemic optic neuropathy (NAION)? Curr Opin in Ophthalmol 2015,26(6):458-463


De Lott LB, Burke JF, and Michigan Neuro-ophthalmology Research Consortium. The use of laboratory markers in deciding whether to perform temporal artery biopsy. JAMA Ophthalmol 2015, 133(5):605-8


Wall M, Kupersmith M, Kieburtz K, Corbett J, Feldon S, Friedman D, Katz D, et al. The Idiopathic Intracranial Hypertension Treatment Trial. Clinical profile at baseline. JAMA Neurol 2014, 71(6):693-701


Wall M, McDermott M, Kieburtz K, Corbett J, Feldon S, Friedman D, Katz D, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the Idiopathic Intracranial Hypertension Treatment Trial. JAMA 2014, 311(16):1641-1651


Vision and Lupus. Lupus Now, Spring 2014


MedLink Neurology. Sixth nerve palsy review. 1998-


Katz DM. Neuroclinical journal review. Journal of Neuro-ophthalmology. 2003, 23(2):170-

175


Katz DM, commentator on: Remigio D and Wertenbaker C. Post-operative bilateral vision

loss. Surveys of Ophthalmology 2000, 44:426-432


Katz DM, Trobe JD, Cornblath WT, Kline LB. Ischemic optic neuropathy following lumbar spine surgery. Archives of Ophthalmology.   1994, 112 (7): 925-931


Katz DM, Trobe JD, Dauser R, Marazsko K.  Shunt failure without ventriculomegaly proclaimed by ophthalmic findings. Journal of Neurosurgery. 1994,81:721-725


Waniewski RA, Katz DM, Kimelberg HK. Low-affinity binding of 3H-imipramine to primary astrocyte cultures. Biochemical Pharmacology. 1987; 36 (5):639-46


Kimelberg HK, Katz DM. Regional differences in 5-hydroxytryptamine and catecholamine uptake in primary astrocyte cultures. Journal of Neurochemistry. 1986;47:1647-52


Kimelberg HK, Katz DM. High-affinity uptake of serotonin into immunocytochemically identified astrocytes.  Science. May 17, 1985; 228:889-91


Katz DM, Kimelberg HK.  Kinetics and autoradiography of high affinity uptake of serotonin by primary astrocyte cultures.  Journal of Neuroscience. 1985; 5 (7): 1901-8

           

Kimelberg, HK, Katz DM. High-affinity uptake of 3H-serotonin by primary astrocyte culture from rat brain. Society for Neuroscience Abstracts. 1984; 10:766


ABSTRACTS:


DeLott L, Anderson D, Dotan S, Katz D, et al. Applying laboratory data in temporal artery biopsy decisions. North American Neuro-Ophthalmology Society Meeting, March, 2014, Puerto Rico


Osborne B, Katz DM, Khan N. Bilateral compressive optic neuropathy due to idiopathic hyperostosis of the skull. North American Neuro-Ophthalmology Society Meeting, February, 2013, Snowbird, UT


Shah D, Mark A, Katz DM. “Dark Halo Sign” on T1-Weighted Images: An

Ominous Finding of Aggressive Sphenoid Sinusitis. American Society of Neuroradiology, May,

2010, Boston, MA


Katz DM, Trobe JD, Cornblath WT, Kline LB. Ischemic optic

neuropathy following lumbar spine surgery. North American Neuro-Ophthalmology Society

Meeting, March 1993, Big Sky, MT


Katz DM, Trobe JD, Dauser R, Marazsko K.  Shunt failure without ventriculomegaly proclaimed by ophthalmic findings. North American Neuro-Ophthalmology Society Meeting, March 1993, Big Sky, MT


CLINICAL TRIALS:


Phase IV 5-10 year observational trial (Verismo) of ocrelizumab for the treatment of multiple sclerosis to determine incidence of breast cancer and other malignancies. 2019-


Phase III, randomized, masked trial comparing maximal medical therapy vs. optic nerve sheath fenestration vs. ventriculoperitoneal CSF shunting in subjects with moderate to severe vision loss due to idiopathic intracranial hypertension (SIGHT). 2019-2020


Phase III, randomized, double-masked evaluating the efficacy and safety of RPh201 (Regenera) subcutaneously twice weekly to test for regeneration in patients with stable non-arteritic anterior ischemic optic neuropathy (NAION). 2018-2020


Open-label intervention study assessing the efficacy and safety of long-term treatment with idebenone (Raxone) in Leber’s Hereditary Optic Neuropathy. 2017-2021


Phase II/III, randomized, double-masked, sham-controlled trial of QPI-1007 delivered by single or multi-dose intravitreal injection(s) to subjects with acute non-arteritic anterior ischemic optic neuropathy (NAION). 2016-2019


Multi-center international trial collecting retrospective data on patients with meningiomas affecting the anterior visual pathways who had undergone surgery. Coordinated by the University of Michigan/WK Kellogg Eye Center. Jonathan Trobe, MD director, 2015-17


Non-Arteritic Ischemic Optic Neuropathy natural history trial (NAION PERCEPTION Study). 2013-2016


ESTEEM phase IV trial of Tecfidera (dimethyl fumarate) for relapsing-remitting MS. 2013-2021


Multi-center US trial collecting data on 400 patients with giant cell arteritis. Coordinated by the University of Michigan/WK Kellogg Eye Center. Jonathan Trobe, MD director, 2012-14


Multi-center US trial collecting data on minority patients with giant cell arteritis. Coordinated by Wills Eye Hospital. 2013


Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Phase III, placebo controlled clinical trial. Principal Investigator. NIH/NEI sponsored. 2010-14


Evaluate Patient Outcomes Study (EPOC). Phase IV safety and tolerability of fingolimod in MS. Principal Investigator. 2011-14


STATIFY-2. JC virus antibody program in patients with MS. Phase IV study. Principal Investigator. 2010-14


Tysabri Global Observational Program in Safety (TYGRIS). Phase IV study. Principal Investigator. 2010-14


PRESENTATIONS:


Latest treatment for optic neuritis and MS. First annual Ophthalmology Times EyeConference, virtual meeting, December, 2021


What’s new in MS. Holy Cross Hospital Neuroscience Symposium, Silver Spring, MD November, 2021


Transient visual loss and visual field interpretations. Montgomery County Optometric Society meeting, Bethesda, MD September, 2019


Management of binocular diplopia. DC regional optometry review course, McLean, Va, October, 2018


Diplopia Review. Montgomery County Optometric Society meeting, Bethesda, MD, March, 2018


Novel treatment for NAION (QRK207 clinical trial). Montgomery County Optometric Society meeting, Bethesda, MD, October, 2017.


Giant Cell Arteritis and Non-Arteritic Ischemic Optic Neuropathy Review. DC regional optometry review course, McLean, VA, June, 2017


Non-Arteritic Ischemic Optic Neuropathy Review. Howard University Ophthalmology Residents’ Day. June, 2017


What’s new in MS. Howard University Ophthalmology Residents’ Day. June, 2016


What’s new in MS. Montgomery County Optometric Society meeting, Bethesda, MD, May, 2016


What’s new in MS. Washington Clinical-Pathological Society meeting, February, 2016


Severe optic neuritis and/or transverse myelitis most often due to NMO/Devic’s in minority population. Howard University Ophthalmology Residents’ Day. June, 2015


Parkinson’s Disease and Visual Issues. Leisure World Parkinson’s Society Meeting, March, 2015


Idiopathic Intracranial Hypertension Treatment Trial presentation of clinical trial results. Georgetown University Neurology Department dinner meeting, Chevy Chase, MD October, 2014


Giant Cell Arteritis Review. Montgomery County Optometric Society meeting, Bethesda, MD, September, 2014


Wernicke’s encephalopathy misdiagnosis. Invited lecturer, Virginia Society of Eye Physicians & Surgeons Annual Meeting. Richmond, VA, June, 2014


IgG4-Related orbital inflammation, a new entity with systemic manifestations. Washington Clinical-Pathological Society meeting, May, 2014


Review of blepharospasm. Benign Essential Blepharospasm Research Foundation (BEBRF) meeting. Holy Cross Hospital, October, 2013


IgG-4 may be a common cause of orbital inflammation. Howard University Ophthalmology Resident’s Day. June, 2013


Case presentations at the Washington Hospital Center/Georgetown Neuro-ophthalmology Saturday Conferences, November 1997-


Idiopathic intracranial hypertension and papilledema review. Montgomery County Optometric Society CME meeting, Bethesda, MD, May, 2013


Neuro-ophthalmological diagnoses you can’t afford to miss. Montgomery County Optometric Society meeting, Bethesda, MD, March, 2013


Atypical mad cow disease vs. Wernicke’s encephalopathy. Washington Clinical-Pathological Society meeting, January, 2013


Vision issues and Parkinson’s Disease. Parkinson Foundation of the National Capital Area. November, 2012


A victim of herd mentality. Invited lecturer, University of Michigan/Kellogg Eye Center Alumni Day. September, 2012


Could giant cell arteritis be caused by an infection? Howard University Ophthalmology Residents’ Day. June, 2012


Ophthalmological complications of the new MS drug, Fingolimod. Howard University Ophthalmology Residents’ Day. June, 2011


Progressive Multifocal Leukoencephalopathy in a previously healthy 70-year-old male. Washington Clinical Pathological Society meeting, October, 2011


Idiopathic Intracranial Treatment Trial. Howard University Ophthalmology Residents’ Day. June, 2010

                                                                                                           

Is there treatment for non-arteritic anterior ischemic optic neuropathy? Howard University Ophthalmology Residents’ Day. June, 2009


Ocular coherence tomography in optic neuritis/MS. Howard University Ophthalmology Residents’ Day. June, 2008


Toxic optic neuropathies. Howard University Ophthalmology Residents’ Day. June, 2007


What’s new in MS. Howard University Ophthalmology Residents’ Day. June, 2006


Ischemic optic neuropathy update. Howard University Ophthalmology Residents’ Day. June, 2005


Intracranial hypotension causing meningeal enhancement and sixth nerve palsies. Howard University Ophthalmology Residents’ Day. June, 2004


Steroid dependant optic neuropathy due to neuro-sarcoidosis. Howard University Ophthalmology Residents’ Day. June, 2003         


Unexplained bilateral vision loss in a young female due to occult macular cone dystrophy. Howard University Ophthalmology Residents’ Day. June, 2002


Update on optic neuritis and its relationship to MS. Presented at the Howard University Ophthalmology Residents’ Day. June, 2001

                                                                                                                                   

Unusual cause of idiopathic intracranial hypertension. Presented at the Howard University

Ophthalmology Residents’ Day. June, 2000

                                                                                                                                                           

Neuro-ophthalmologic complications of ventriculo-peritoneal shunt failure. Presented at the

Howard University Ophthalmology Residents’ Day. June, 1999


Optic neuritis and diplopia in multiple sclerosis. Presented at the Fairfax Hospital Multiple Sclerosis Society. November, 1999        


Risk factor modification in stroke prevention. Presented at the Suburban Hospital Outreach

Center. May, 1998

                                                                                                                                                           

Results of the Optic Neuritis Treatment Trial. Grand rounds presentation at MetroWest Medical

Center, Framingham, MA. January, 1994


Revised 11/17/2021